Botanical species · safety record

Commiphora myrrha

The EFSA Compendium of Botanicals holds 6 constituent measurements and 5 adverse-effect records for Commiphora myrrha. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Commiphora myrrha (Nees) Engl.

6Constituent measurements

5Safety records

5Cited sources

393Licensed products (Canada)

Also recorded as

Commiphora molmol (Engl.) Engl. ex Tschirch

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 393 licensed products naming Commiphora myrrha as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA
solid

Source material stated

Balsam
Bark resin
Bark resin (vinegar-prepared)
Branch(es)
Bush
Commiphora myrrha - stem resin
Flower buds
Gum

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Cinnamaldehyde	—	—	—	—	Resolve DOI
Curzerenone	Unspecified	Essential oil	≥ 0.9 Percent	GC*GC/MS	Resolve DOI
Curzerenone	Unspecified	Essential oil	≤ 1.4 Percent	GC*GC/MS	Resolve DOI
Curzerenone	—	Solvent extraction	—	Chromatographic tests	Resolve DOI
Eugenol	—	—	—	—	Resolve DOI
Sesquiterpene alkaloids	—	Solvent extraction	—	Chromatographic tests	Resolve DOI

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Neurotoxicity	Neurologic: central nervous system	—	—	House mouse (as animal)	Acute toxicity	Resolve DOI
Not stated	Urogenital	—	—	House mouse (as animal)	Chronic/long term toxicity	Resolve DOI
Not stated	Cardiovascular / haematological	—	—	House mouse (as animal)	Chronic/long term toxicity	Resolve DOI
Hemopoietic	Cardiovascular / haematological	—	—	Goat (as animal)	Short-term toxicity	No resolvable identifier
Hemopoietic	Cardiovascular / haematological	—	Solvent extraction	Rat (as animal)	Short-term toxicity	No resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Rao, RM., Khan, ZA., Shah, AH. Toxicity studies in mice of Commiphora molmol oleo-gum-resin. Journal of ethnopharmacology, 2001, vol. 76, no. 2, p. 151-154. DOI
Omer, SA., Adam, SEI. Toxicity of Commiphora myrrha to goats. Veterinary and human toxicology, 1999, vol. 41, no. 5, p. 299-301.
Omer, SA., Adam, SEI., Khalid, HE. Effects on rats of Commiphora myrrha extract given by different routes of administration . Veterinary and human toxicology, 1999, vol. 41, no. 4, p. 193-196.
Marongiu, B., Piras, A., Porcedda, S., Scorciapino, A. Chemical composition of the essential oil and supercritical CO2 extract of Commiphora myrrha (Nees) Engl. and of Acorus calamus L. . Journal of agricultural and food chemistry, 2005, vol. 53, no. 20, p. 7939-7943. DOI
Zhu, NQ., Kikuzaki, H., Sheng, SQ., Sang, SM., Rafi, MM., Wang, MF., Nakatani, N., DiPaola, RS., Rosen, RT., Ho, CT. Furanosesquiterpenoids of Commiphora myrrha. Journal of natural products, 2001, vol. 64, no. 11, p. 1460-1462. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature